Amgen and Onyx Pharmaceuticals, Inc. have entered an agreement under which Amgen will acquire all outstanding shares of Onyx for $10.4 billion in cash. Onyx, a global biopharmaceutical company, develops and commercializes innovative cancer therapies. The transaction is expected to close in 4Q13, subject to customary closing conditions.   Onyx has a growing multiple myeloma franchise, including Kyprolis (carfilzomib) for Injection, which is approved in the U.S. In addition, Onyx has three partne...